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Summary 
GAGA is a nuclear protein encoded by the Trithorax-like gene in Drosophila 
that is expressed in at least two isoforms generated by alternative splicing. By 
means of its specific interaction with DNA, GAGA has been involved in 
several nuclear transactions including regulation of gene expression. Here we 
have studied the GAGA519 isoform as a transcription factor. In vitro, the 
transactivation domain has been assigned to the 93 C-terminal residues 
which corresponds to a glutamine-rich domain (Q-domain). It presents an 
internal modular structure and acts independently of the rest of the protein . 
In vivo, in Drosophila SL2 cells, Q-domain can transactivate reporter genes 
either in the form of GAGA or Gal4BD-Q fusions, whereas a GAGA mutant 
deleted of the Q-domain can not. Our results give support to the notion that 
GAGA can function as a transcription activating factor.  
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Introduction 
Transcription of the homeotic and segmentation genes is a highly regulated 
process in Drosophila in which many different factors exert positive and 
negative effects. Some of those genes including engrailed (en), Ultrabithorax 
(Ubx), even-skipped (eve), fushi tarazu (ftz), and Krüppel (Kr) 
characteristically present multiple binding sites clustered in their promoters 
(with a consensus sequence GAGAG) for a factor named GAGA. The 
expression of Ubx, en and ftz  has been shown to be clearly regulated by 
GAGA in vivo (1,2). This is also likely for the other genes listed above. The 
promoters of some of the heat shock proteins gene family also contain GAGA 
binding sites -some of them remarkably long- and are also expected to be 
under GAGA factor regulation. GAGA is a sequence-specific transcription 
factor organized in several domains. At the N-terminus there is a BTB/POZ 
domain (POZ) which is required for oligomerization (3,4). In a central position, 
a single Zn2+-finger surrounded by three short basic regions conforms the 
DNA-binding region (DBD) that specifically recognizes the GAGA binding 
sites (5,6). At the C-terminus there is a glutamine-rich domain (herein referred 
as Q-domain) still without a defined function.  It was speculated to be a 
transactivation domain because its composition resembles that of the 
glutamine-rich family of transactivation domains (7). More recently, however, 
functions on DNA distortion and protein multimerization have been attributed 
to the Q-domain (8,9). 
GAGA is encoded by the essential Trithorax-like (Trl) gene and is of maternal 
effect (1). Expression of Trl gives rise to at least two different proteins 
generated by alternative splicing. These two isoforms (GAGA519 and 
GAGA581) share the initial 381 residues and only diverge at the C-terminus, 
where both proteins still present a similar glutamine-rich domain but of 
different lengths (10). At the genetic level, Trl mutants downregulate the 
expression of homeotic genes, as for instance Ubx (1) and some of the 
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mutants display an enhancement  in Position Effect Variegation (PEV). On 
the other hand, transient transfection experiments demonstrated a stimulation 
of transcription only from reporters containing GAGA-binding sites in vivo 
(10,11). In vitro, GAGA was shown to stimulate transcription from several 
promoters only when bearing GAGA binding sites (12,13). However, addition 
of GAGA to some fly embryo extracts did not result in an increase in 
transcriptional activity. This fact, along with the lack of net activation observed 
with hsp promoters, prompted the suggestion that GAGA was acting as an 
antirepressor (14,15).  
GAGA was also shown to have an effect in remodeling the chromatin 
structure of the hsp70, hsp26  and ftz  promoters (16-18). However, this 
nucleosome remodeling does not appear to be tightly associated to the 
presence of GAGA since it can take place with Gal4BD alone on synthetic 
promoters carrying Gal4-binding sites. Moreover, if Gal4-BD is fused to a 
transactivation domain then stimulation can occur, thus separating both 
processes (19).  
Here we report the biochemical characterization of the GAGA domains 
functional in transcription. Our results indicate that deletion of the glutamine-
rich C-terminal domain (Q-domain) abolishes the transcriptional activity, in 
vitro and in vivo. The Q-domain presents a modular structure in which the 
glutamine residues are dispensable for the stimulatory activity. The 
transcriptional activity of GAGA is reduced but not abolished by deletion of 
the POZ domain in vitro.  
 
Materials and methods 
DNA constructions, and protein expression and purification 
Constructs for recombinant protein expression in E. coli  were cloned as His6-
tagged fusions into pET14b expression vector (Novagen). Constructs 
expressing full-length GAGA, ∆POZ, and DBDGAGA have been recently 
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described (3,20). Construct pET14b-GAGA-∆Q lacking the Q-rich C-terminal 
domain was obtained by inserting aNdeI-EcoRV fragment from the pET14b-
GAGA into NdeI and BamHI (filled-in with Klenow enzyme) sites of pET14b. 
pET14b-GAGA-∆3 was obtained by replacing the SfiI-HindIII fragment of 
pET14b-GAGA by the SfiI-HindIII fragment from pET14b-Gal4-Q. pET14b-
GAGA-∆4 was constructed by inserting at the EcoRV site in the GAGA 
sequence a blunt-ended DNA fragment generated by PCR and spanning 
P445 to Q519 residues of GAGA. pET14b-GAGA∆Q-VP16 was constructed 
by ligation of the VP16 transactivation domain obtained by PCR from pJL2 to 
the pET14b-GAGA-∆Q. 
Gal4BD was subcloned into pET14b using PCR. Gal4BD-Q was obtained by 
inserting an EcoRV-EcoRV fragment  from pET14b-GAGA at the SmaI site of 
the pET14b-Gal4BD construct. Constructs Gal4BD-Q∆1, -Q∆2, -Q∆3, and -
Q∆4 were obtained by PCR from the Gal4BD-Q construct and are described 
in Fig. 3A. All constructs were verified by DNA sequencing. 
Plasmid pJL2 expressing Gal4-VP16 fusion was kindly provided by M. Carey 
and M. Ptashne (Harvard University). 
Constructs AdML50[180], (CT)22-AdML50[180], WT[180] and 8xGal4-
WT[180] have been previously described (20,21). 
Expression and purification of His6-tagged recombinant proteins was carried 
out in E. coli BL21(DE3) strains essentially as described before (20,21). The 
Gal4-VP16 fusion was expressed and purified as described (22). 
In vitro transcription assays  
In vitro transcription assays using unfractionated HeLa cell nuclear extracts 
contained 30-50 µg of protein extract, variable amounts of recombinant 
proteins and 200 ng of supercoiled DNA template. Templates used contained 
either a CT22 sequence or 8 Gal4 binding sites cloned immediately upstream 
of a minimal TATA box and fused to a G-less cassette. Reactions were in a 
final volume of 25 µl and contained 3.5 mM MgCl2, 0.8 mM 3'-O-Me-GTP 
Vaquero et al.  6 
(Amersham-Pharmacia Biotech), 0.4 mM ATP, 0.4 mM CTP, 20 µCi  [α−32P] 
UTP (800 Ci/mmol) adjusted to 1 µM with cold UTP, 3 units RNAse T1, 1.5 
mM DTT, 2% PEG 8000, 0.2 mM EGTA, 33 mM HEPES-KOH, pH 7.9;  
nuclear extract was added up to 10 µl in D-buffer (0.1 M KCl, 0.2 mM EDTA, 
0.5 mM DTT, 0.1 mM PMSF, 20% glycerol, 20 mM HEPES, pH 7.9). 
Reactions were typically incubated for 60 min at 30°C, and terminated by 
SDS addition, phenol extraction and ethanol precipitation as described before 
(23). For the study of GAGA deletion mutants and since we observed some 
variability from experiment to experiment, all experiments were run alongside 
with GAGA titrations to correct for potential deviations. Drosophila embryo 
nuclear extracts (SNF) prepared as in (24) were a generous gift  from Peter 
Becker (EMBL). In vitro transcription assays were performed as above except 
that reactions were allowed to proceed for 35 min at 26°C. 
All the in vitro transcription results were quantified from the corresponding 
autorradiographs using a Molecular Dynamics laser microdensitometer. 
 
Transient cell transfections 
 
Drosophila expression plasmid Act5CPPA (kindly provided by G. Jiménez, 
IBMB, Barcelona) was used to subclone in its polylinker region GAGA, 
GAGA-∆Q, GAGA-∆POZ, GAGA∆Q-VP16, Gal4BD, Gal4BD-Q, and Gal4BD-
VP16 constructions reported above. To study  the effects of the Gal4-fusions, 
reporters 5xGal4-hsp70TATA-βgal and hsp70TATA-βgal were constructed by 
inserting either 5xGal4 binding sites-hsp70 TATA box (derived from pUAST 
construct) and a hsp70 TATA box (derived from pWHL construct) in the 
pβgal-basic vector (Clontech), respectively. pUAST and pWHL were kindly 
provided by S. González (IBMB, Barcelona). To study the effects of GAGA 
mutants fragments containing a d(GA.TC)22 sequence were inserted in both 
orientations in the hsp70 TATA box-βgal construct described above giving 
rise to plasmids named and CT22-hsp70TATA-βgal and GA22-hsp70TATA-
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βgal. A CMV-luciferase reporter plasmid was always used in co-transfection 
assays as an internal control for transfection efficiency. 
 Drosophila S2 cells were grown in Schneider's insect medium (Sigma) 
containing 10% fetal calf serum (Gibco-BRL) and gentamycin. Cells were 
kept at 1-8x106 cells/ml. For transfection, 2-3x106 cells in 5 ml of medium 
were plated onto 6 cm diameter tissue culture dishes and allowed to stand for 
24 h at 25°C. Cells were then transfected using the calcium phosphate 
technique as described (25) using 0-10 µg of test constructs, 5 µg of reporter 
constructs, 7 µg of pUC19 and 0,5 µg of CMV-luciferase construct. The final 
volume and the total amount of DNA was kept constant to 20 µg by the 
addition of the amounts of Act5PPA vector and water required in each case. 
After incubation with precipitates for 48 hr. at 25°C, cells were lysed and β-
galactosidase activity measured  using the β-galactosidase gene reporter kit 
(Boehringer-Mannheim). As an internal control, luciferase activities were 
assayed using the Luciferase activity assay kit (Promega). β-galactosidase 
activities were corrected respect to luciferase activities to normalize for 
transfection efficiency.  
 
Results 
The Q-domain of GAGA is necessary for the transcriptional activity in 
vitro  
The study of GAGA as a transcription factor was initially carried out in an 
heterologous system using nuclear extracts from HeLa cells in vitro. The 
rationale behind this was to avoid the presence of GAGA in crude fly embryo 
nuclear extracts. HeLa cells provided a convenient system because the 
general transcription machinery is rather conserved between human and 
Drosophila and also because GAGA is not expected to exist in human cells. 
In fact, we have previously shown that there are no proteins in HeLa nuclear 
extracts that can either footprint or stimulate transcription from templates 
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containing GAGA binding sites (3,20). With this approach we tested the 
activities of several deletion mutants as outlined in Fig.1A using a template 
DNA containing a G-less cassette fused to a promoter that contained a 
minimal TATA box (derived from the AdML promoter) and a d(CT)22 
sequence, which acted as a GAGA binding sequence, inserted shortly 
upstream of the TATA box (at position -50 respect to the transcription start 
site). All experiments were done by titrating the amount of recombinant 
protein added to a fixed amount of nuclear extract and template DNA. 
Maximal activation rates observed after normalization to recovery controls 
were considered. The maximal activation rates obtained with full-length 
GAGA (GAGA in Fig.1A,B) were around 15-fold respect to the control and 
that was taken as 100% of activation; all other numbers are referred to it and 
represent the average of at least three independent experiments. In the 
presence of high amounts of GAGA a significant drop in transactivation was 
observed (Fig.1B, compare lanes 2-5 in the upper gel, and lanes 10-14 in the 
lower gel). With this approach we assayed the effect of GAGA mutants 
deleted of some domains. As controls DBD(GAGA) and POZ(GAGA) which only 
retained the binding domain and a long version of the POZ domain 
respectively, showed no activation at all (Fig.1A,B). Deletion of POZ domain 
generated a moderate reduction which resulted in a 76% of the maximal 
activity (Fig.1A,B, GAGA-∆POZ). A clear drop in transcription was also 
observed at amounts of GAGA-∆POZ higher than GAGA and may reflect 
squelching in both cases. Deletion of the Q-domain resulted in a much larger 
reduction but not a complete inactivation, and a residual 23% of maximal 
activity was obtained (Fig.1A,B, GAGA-∆Q). DNAse I footprinting analysis 
showed that GAGA and GAGA-∆Q interact with similar intensity and identical 
specificity to the d(GA.TC)22 sequence, thus ruling out any potential 
impairment in its binding to the template DNA (results not shown). Therefore, 
the clear drop in activity can only be attributed to a lack in the transcriptional 
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activity of the GAGA-∆Q mutant. GAGA-∆POZ capabilities to bind the 
template DNA were previously studied and shown to be of the same 
specificity and affinity as intact GAGA (3). From these results, it can be 
concluded that Q-domain has a major contribution to the observed 
transcriptional activity.  
 
Q-domain is a modular transactivation domain
 
In order to study the contribution of the Q-domain independently of the other 
domains of GAGA protein, fusions to the Gal4 DNA binding domain were 
prepared. This approach also allowed to determine whether Q was a 
separable domain that could transactivate from heterologous DNA binding 
sites, as characteristically described for classical transactivation domains 
(22,26). In vitro transcription experiments were carried out in HeLa cell 
nuclear extracts and used a template DNA containing a G-less cassette fused 
to an artificial promoter that contained a minimal  artificial TATA box and 8 
tandemly repeated binding sites for Gal4 (inserted upstream of position -50). 
Reactions were performed as described in Material and methods and are 
shown in Fig.2. Gal4BD-Q showed a remarkably strong activity in these 
assays reaching 20 to 25-fold activation from promoters containing Gal4-
binding sites (Fig.2B, Gal4BD-Q, compare lanes 1 in all three panels with 
lanes 8 in the upper and middle panels and lane 3 in the lower panel); there 
was no activation at all when the same promoter but lacking the Gal4 binding 
sites was used (not shown). As a control Gal4BD (comprising residues 1-147) 
was titrated and showed a marginal activation as noted before (26).  
Similar results were also obtained when Gal4BD-Q was assayed in a 
Drosophila embryonic nuclear extract using exactly the same template DNA 
(Fig.2C). Titration of recombinant Gal4BD-Q in Drosophila SNF extracts 
resulted in a ~12-fold maximal increase in transcription (Fig. 2C, lane 3). 
Gal4BD-VP16 used as a control stimulated transcription up to ~38-fold (Fig. 
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2C lanes 7-9). In these extracts, however, titration of GAGA factor did not 
produce any increase in transcription rates (data not shown) in agreement 
with results previously published (14).  
 
As it can be appreciated in Fig.2A, Q-domain can be roughly subdivided into 
three regions according to the presence of long runs of glutamine residues. 
Mutants -Q∆1 to -Q∆3 were generated by progressive deletion of the 
sequences between glutamine tracks as depicted in Fig.2A, and their 
transcriptional efficiencies determined in transcription assays in vitro in HeLa 
nuclear extracts using the same template DNA containing Gal4 binding 
sequences. As above, quantifications of the activity represent the average of 
at least three independent experiments and are referred to Gal4BD-Q 
maximal activity taken as 100%. The results showed that Gal4BD-Q∆3 
mutant which only retained 18 residues from the Q-rich domain and none of 
the long glutamine runs was still remarkably active (60% of maximal). Shorter 
deletions (-Q∆2 and -Q∆1) showed increased levels of activity suggesting 
that several regions in the Q-domain may contribute to stimulate transcription. 
This interpretation was further supported by the fact that the internal deletion 
of the 18 N-ter residues of the Q-domain (-Q∆4) did not abolish 
transactivation but only reduced it to a 78% respect to the entire Q-domain.  
Similar results were obtained when equivalent mutants in the GAGA context 
were assayed in HeLa nuclear extract using the template containing the 
d(CT)22 sequence described above. Fig.3 shows that in the GAGA context 
deletion of most of the Q-domain except of the 18 N-ter most residues 
(GAGA-∆3) still retained more than 50% of the maximal transcriptional activity 
whereas the internal deletion of this 18 amino acid region (GAGA-∆4) 
retained more than 85% of maximal activation. Long glutamine runs do not 
seem to be directly required.  
Vaquero et al.  11 
All these results indicated that Q-domain is an independent, transportable 
transactivation domain with a modular architecture in which the different 
regions cooperate to reach maximal activity.  
 
 
GAGA transcriptional activity depends on Q-domain in vivo 
GAGA was shown earlier to be able to stimulate transcription in vivo in 
transiently transfected Drosophila SL2 cells (10,11). Here, the requirement of 
the Q-domain for this transcriptional activity was studied in vivo by transient 
transfection of constructs expressing Gal4BD-Q, GAGA and GAGA-∆Q 
proteins in SL2 cells.  
Initially, SL2 cells were transiently transfected with constructs expressing 
Gal4BD-Q, and Gal4BD-VP16 and Gal4BD as positive and negative controls 
respectively, under the control of the constitutive actin5 promoter and their 
activities assayed. The results showed (Fig.4A) that Gal4BD-Q stimulated 
transcription from the 5xGal4-βgalactosidase reporter up to 8-fold (stripped 
boxes) in good agreement with the in vitro results presented above. Gal4BD-
VP16 reached up to ~571-fold stimulation (hatched boxes) and showed to be 
a really strong activator in vivo as described (27). On the other hand, Gal4BD 
alone did not stimulate transcription at all (gray boxes).  
In a second set of experiments, GAGA and GAGA-∆Q were similarly assayed 
using a β-galactosidase reporter bearing a (CT)22 sequence just upstream of 
the minimal hsp70 promoter. In these experiments, a high background level 
likely due to the presence of endogenous GAGA was observed. The results 
showed that GAGA overexpression stimulated transcription up to ~2-fold 
(Fig.4B, stripped boxes). This stimulatory effect is lower than the observed by 
Kornberg and co-workers (11) but similar to the reported by Elgin and co-
workers (10). In any case, GAGA-∆Q did not stimulate transcription at all, 
instead a repression of the background level was observed (Fig.6B, stippled 
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boxes). As a control for this negative result, a construct expressing GAGA∆Q-
VP16 was used and showed up to a ~10-fold stimulation of transcription 
(Fig.6B, hatched boxes). This result rouled out  the possibility that the lack of 
activity of GAGA-∆Q could be due to any incorrect intracellular localization, 
since the VP16 domain used did not include any nuclear localization signal. 
Additionally, these results also indicated that the folding of the GAGA-∆Q 
moiety seemed to be correct in vivo. Finally, GAGA stimulation of 
transcription was dependent on the presence of GAGA binding sequences in 
the promoter and was insensitive to heat-shock treatment of the transfected 
cells (results not shown).  
All these results indicate that the transcription stimulatory activity of GAGA 
depends on the Q-domain which can act independently of the rest of the 
protein, in vitro and in vivo. 
 
Discussion 
From the knowledge accumulated to date, GAGA seems to be a multi-
purpose factor that is involved in many different nuclear processes including 
gene regulation, chromatin remodeling, and nuclear division (2). GAGA is 
transcribed from the Trl gene into at least two different mRNAs generated by 
alternative splicing. They give rise to GAGA519 and GAGA581 forms which 
only differ at the C-terminal domain. In both cases there is a glutamine-rich 
domain but the exact composition and length are different.  
Initial studies showed that GAGA could stimulate transcription in Drosophila 
both in vitro and in vivo (11,12,14,28). Here we have shown that this 
stimulatory activity depends on the C-terminal Q-domain  both in vitro and in 
vivo. 
 
On empirical basis, we have defined Q-domain of GAGA519 as comprising 
residues 426 to 519, since its deletion causes a major drop in the 
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transcriptional activity of GAGA-∆Q, and its fusion to the Gal4 binding domain 
results in a active chimaeric protein in vitro and in vivo. GAGA-∆Q shows a 
residual 23% of activity that might be due to the uncovering of a cryptic and 
weak transactivation region. A similar effect has been observed for example 
with the yeast Gal4 transcription factor (26). An extended C-terminal deletion 
up to residue 390 did not reduce it further (not shown). Deletion of the POZ 
domain has a relatively minor effect on transcription in vitro. POZ domain has 
been previously shown to be responsible for GAGA oligomerization in vitro  
(3,4). Moreover, GAGA-∆POZ binding to DNA was shown to be progressive 
and non-cooperative as a result of its monomeric state whereas GAGA bound 
cooperatively and was present in an oligomeric form. A reduced maximal 
activation of GAGA-∆POZ was also noticed in those experiments using 
different templates. These results were interpreted as to the lack of 
cooperativity among the GAGA-∆POZ molecules could not properly 
reorganize the promoter and render a fully active complex (3,4).   
Q-domain has been shown to work independently of the rest of the GAGA 
protein since it also works very efficiently in Gal4BD fusions. In this context, 
Q-domain has been dissected further and at a resemblance to other classical 
transactivation domains, like those of VP16 or Sp1 for instance, has shown to 
possess an internal structure. We observe the presence of three different 
regions which seem to work synergistically, although none of them seems to 
be absolutely required. This is indicated by the results obtained with the 
deletion mutants. Those mutants were essentially designed to remove 
sequence blocks from glutamine run to glutamine run. In this way, ∆1 deleted 
the C-ter Q-rich stretch, ∆2 deleted up to the central Q-rich stretch plus the G-
run, and ∆3 deleted up to the most N-terminal Q-stretch leaving a peptide 
only 18-residues long. All of them retained transactivation potentials ranging 
from 90 to 60%, respectively. Mutant ∆4, in which the 18-residues long 
peptide was deleted while leaving intact the rest of the domain, showed the 
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same transactivating potential as mutant ∆2 (around 75%). The conclusion is 
that the three regions seem to be functional on their own and synergize. 
Remarkably, the two most relevant mutants, ∆2 and ∆4, showed a very 
similar behavior in the GAGA protein context strongly suggesting that Q-
domain also works, irrespective of the rest of the protein, as a transactivating 
domain in GAGA.  
Homopolymeric stretches of glutamines or prolines fused to Gal4BD can 
stimulate transcription when they include 10 or more uninterrupted residues 
(29). The results obtained with mutant ∆3 suggest that at least the glutamine 
runs do not seem to be the only activation motif in the Q-domain. In any case, 
an uninterrupted stretch of 7 glutamine residues (or 12 if we accept two 
interruptions) is the longest Q-run that can be found in the GAGA activation 
domain. 
 
For the sequence analysis, and as mentioned above, Q-domain was 
subdivided into three regions of unique sequence - proximal, intermediate, 
and distal - separated by glutamine runs. Sequence comparisons of these 
three regions by pairs detected very weak homologies. Similarly, none of 
those sequences seem to have any clear homologue in other glutamine-rich 
transcription factors (not shown). However, when the four GAGA factors 
reported so far (i.e. D. melanogaster 581, and D. virilis GAGA-A and -B) are 
compared, reasonably conserved homologies for distal and proximal regions 
appear, being less apparent for the intermediate region (Fig.5). In addition, 
homologies to the distal region always appear at the C-terminal part of the 
domain whereas homologies to the proximal region always appear to the N-
terminal part of the domain. This colinearity is lost for the intermediate region. 
All these GAGA proteins show a strong sequence conservation at the N-
terminal portion and despite they differ at the glutamine-rich C-terminal 
domain, they also show a similar overall structure and composition (10,30). 
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The fact that the variable region has partially conserved the relevant motifs 
described above, suggests that the other members of this group could also 
retain some transcriptional activation function. 
 
GAGA was put into question as a real activator because of its unability to 
stimulate transcription in Drosophila SNF extracts devoid of histone H1 while 
it could stimulate transcription when histone H1 was added back. This result, 
previously reported by Kadonaga and co-workers, was considered to be the 
indication that GAGA was acting as an antirepressor rather than a true 
activator (14). Histone H1 was identified in some crude extracts as the 
repressing factor GAGA was counteracting. The lack of GAGA activity in 
SNF-like extracts was then correlated with the absence of histone H1 in these 
extracts (14,24,28). This antirepression activity was subsequently extended 
to Gal4BD-VP16 (31) and, in general, it can be assumed that all activators 
have antirepressor activities. 
Here, we have used a HeLa crude nuclear extract that may contain some 
histone H1 and, therefore, we cannot provide a definite answer to this 
question. Nevertheless, we have previously shown that addition of plasmid 
DNA to compete for histone H1 binding did not reduce GAGA stimulation in 
HeLa extracts suggesting that GAGA was not only acting as an antirepressor 
but also as a true activator (20). In any case, our results clearly show that the 
stimulatory activity of GAGA depends on Q-domain. In addition, using SNF 
extract from Drosophila embryos we found that Gal4BD-Q could also 
stimulate transcription in vitro,  whereas GAGA could not (not shown). Thus, 
it is conceivable that the lack of activity of added GAGA in these extracts may 
be due to some blockage of the Q- or DNA binding domains by some 
factor(s) interacting with GAGA in regions other than Q-domain, or to some 
factor(s) competing for binding to the same DNA sequences (e.g. 
endogenous GAGA). Some recent reports give support to possibilities other 
Vaquero et al.  16 
than the H1 repression mechanism, and should be taken into consideration. 
In particular, the Drosophila gene pipsqueak encodes a POZ-domain 
containing protein which is required in the oogenesis, is highly expressed in 
the early embryo, and binds GAGAG sequences with high specificity (32,33). 
The presence of this factor in large amounts in the extracts may compete or 
at least interfere with GAGA activation. This possibility does not seem to exist 
in HeLa nuclear extracts since we have not found any activity that could bind 
to GAGA sequences or transactivate reporters bearing GAGA binding sites 
((20) and results not shown).  
In summary, the properties described here seem to indicate that Q-domain 
acts as a bona fide transactivation domain in vitro because i) acts irrespective 
of the rest of the protein and is transportable; ii) presents an internal modular 
structure; and iii) is functional in SNF extracts in the form of Gal4BD-Q 
fusions. Additionally, GAGA appears to enhance transcription mainly by 
stimulating GTF recruitment and reinitiation (Vaquero et al, in preparation) 
further confirming its properties as a real transactivation factor. 
  
In vivo GAGA can stimulate transcription in SL2 cells ((10,11 ), this work) in a 
Q-domain dependent manner. Deletion of the Q-domain abolishes activation 
and even more transcription levels go below the background. This result can 
be explained by a downregulation of the endogenous GAGA factor activity 
present in SL2 (as detected by western blot analysis and also by comparing 
the activities of templates bearing and lacking GAGA binding sites, not 
shown). We have estimated that endogenous GAGA can transactivate 
templates containing GAGA binding sites ~5-8 fold relative to the same ones 
without them (not shown). Thus, expression of GAGA-∆Q reduced the total 
levels of activation probably because it efficiently competes for binding to the 
GAGA sequences. The presence of the POZ domain may also permit the 
formation of mixed oligomers of both GAGA forms and thus contribute to 
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reduce activation yields. These interpretations are supported in part by the 
fact that expression of a GAGA mutant in which the Q-domain was replaced 
by the VP16 transactivation domain stimulated transcription in vivo but to a 
much lesser extent than observed with Gal4BD-VP16. 
The activation levels obtained by GAGA overexpression in SL2 cells are 
modest (2-fold on the average) compared to the levels reported by Kornberg 
and co-workers (11) but are similar to the levels reported by Elgin and co-
workers (10), and significantly lower than obtained with Gal4BD-Q or 
Gal4BD-VP16. The reasons for the differences are not fully understood but 
might be related to differential responses due to  the several promoters used 
(multimerized engrailed C site vs. synthetic CT22 sequences) as recently 
pointed out (34).  
 
From all the accumulated data, GAGA appears to be a rather complex factor 
involved in a whole series of nuclear events. To carry out all their functions in 
the fly GAGA will probably be under tight regulation by means of 
posttranslational modifications, association with other factors, etc. Here we 
have described its potential to stimulate transcription in a simple system. 
More work is required to define the exact contribution of GAGA in all the 
processes where it is involved and how it is regulated.   
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Legends to Figures 
 
Figure 1. The C-terminal Glutamine-rich domain is the transactivation domain 
of GAGA. A. Scheme of the GAGA mutants assayed (on the left) and results 
of activation (on the right) expressed as a fraction of the maximal activation 
obtained with wild-type GAGA. B. Transcriptional activity of the GAGA 
mutants in an in vitro transcription assay using nuclear HeLa cell extracts. 
Upper panel: Lanes 1, 6 and 12 are controls for basal transcription; Lanes 2-
5 received 11.25, 22.5, 45, and 90 ng of GAGA, respectively; Lanes 7-11 
received 4, 8, 32, 56, and 80 ng of POZ(GAGA) , respectively; Lanes 13-16 
received 2.5, 5, 20, and 35 ng of DBD(GAGA) , respectively. Lower panel : Lane 
1 is a control for basal transcription; lanes 2-5 received 6,25, 12,5, 25, and 
43.75 ng of GAGA-∆Q, respectively; Lanes 6-9, received 20, 40, 80, and 140 
ng of GAGA-∆POZ, respectively; Lanes 10-14 received 2.25, 11,25, 22.5, 45, 
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and 90 ng of GAGA, respectively. Arrows indicate full-length transcripts; * 
denotes a recovery control.  
 
Figure 2.The Q-domain of GAGA transactivates efficiently when fused to 
Gal4BD and shows an internal modular structure. A. Fusion proteins to the 
Gal4BD (residues 1-147) assayed in B are indicated on the left. On the right 
transcriptional rates are expressed as the fraction of the maximal activation 
obtained with the entire Q-domain. B. Increasing amounts of Gal4BD (10, 20, 
and 60 ng), Gal4BD-Q (10, 30, 50, and 100 ng in the upper and central 
panels, and 50, 100, and 150 ng in the lower panel), Gal4BD-Q∆1 (4, 10, 20, 
40, and 60 ng), Gal4BD-Q∆2 (2, 4, 10, 20, and 60 ng), Gal4BD-Q∆3 (2, 4, 8, 
20, and 40 ng ), and Gal4BD-Q∆4 (3, 6, 12, 15, 21, and 36 ng) were assayed 
in Hela nuclear extract as indicated. Lanes 1 and 5 in all three panels did not 
receive any of these proteins and represent basal, non-activated 
transcription. C. Increasing amounts of Gal4BD-Q (20, 50, 75, 100 and 300 
ng, lanes 2-6, respectively) and Gal4BD-VP16 (2.5, 5, and 15 ng, lanes 7-9, 
respectively) were assayed in a SNF Drosophila  embryo extract. Lane 1 is a 
control for basal transcription and received no Gal4 protein. Arrows indicate 
full-length transcripts; * denotes a recovery control, and ** denotes an internal 
translabeled band coming from the embryo extract.  
 
Figure 3. In GAGA  Q-domain is an independent domain and shows  the 
same transactivation potential and internal modular structure. A. Scheme of 
the GAGA mutants assayed (on the left) and results of activation (on the 
right) expressed as a fraction of the maximal activation obtained with wild-
type GAGA. B. Transcriptional activity of the GAGA mutants in an in vitro 
transcription assay using nuclear HeLa cell extracts. Upper panel , increasing 
amounts of GAGA (11.25, 22.5, and 45 ng lanes 2-4, respectively) and 
GAGA-∆3 (0.7, 1.25, 2.5, 5, 10, and 20 ng, lanes 6-11, respectively were 
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assayed); lanes 1 and 5 did not receive GAGA proteins and represent basal 
transcription. Lower panel , increasing amounts of GAGA (5.63, 11.25, 22.5, 
and 45 ng lanes 2-5, respectively) and GAGA-∆4 (1, 2.5, 5, 10, 20, and 40 
ng, lanes 7-12, respectively were assayed); lanes 1 and 6 did not receive 
GAGA proteins and represent basal transcription. Arrows indicate full-length 
transcripts; * denotes a recovery control.  
 
Figure 4. Q-domain can transactivate in vivo in transiently transfected 
Drosophila SL2 cells. A. Gal4BD-Q stimulates transcription in vivo. SL2 cells 
were transiently transfected with increasing amounts of constructions 
expressing Gal4BD (dotted boxes), Gal4BD-Q (hatched boxes), or Gal4BD-
VP16 (cross-hatched boxes). After normalization to the luciferase internal 
control, activation is plotted vs. the amounts of transfected DNA. A scheme of 
the β-galactosidase reporter carrying 5 Gal4 binding sites immediately 
upstream of a hsp70 TATA box is shown below. B. GAGA deleted of the Q-
domain cannot transactivate in vivo. Increasing amounts of constructs 
expressing GAGA (hatched boxes), GAGA-∆Q (stippled boxes), and GAGA-
∆Q-VP16 (cross-hatched boxes) were assayed. After normalization to the 
luciferase internal control, activation is plotted vs. the amounts of transfected 
DNA. A scheme of the β-galactosidase reporter carrying a CT22 sequence as 




 Sequence  alignment of the proximal, intermediate, and distal 
regions of the Q- domain. 
The sequences present in the Q-domain of D. melanogaster GAGA519 in 
between the Q-stretches were used to search for homologies in the D. 
melanogaster GAGA581, and D. virilis GAGA forms A and B. The sequences 
of GAGA519 used for the alignment were residues I427 to Q446 for the 
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proximal region, residues H460 to Q485 for the intermediate region, and 
A491 to Q512 for the distal region. Homologies were studied to the entire 
region immediately C-terminal to the DNA binding domain of the other three 
proteins by using the programs bestfit and boxshade of the GCG package 
and multalin (35). Black boxed residues indicate identical residues, shaded 
boxed residues indicate conserved residues. Consensus sequences are 
shown for each region. All residue numbers refer to their positions in 
GAGA519 only. 










